Ignite Creation Date:
2024-05-06 @ 6:25 PM
Last Modification Date:
2024-10-26 @ 2:47 PM
Study NCT ID:
NCT05656222
Status:
WITHDRAWN
Last Update Posted:
2023-02-16
First Post:
2022-12-09
Brief Title:
Irinotecan and Anlotinib for Epithelioid Sarcoma
Sponsor:
Peking University Peoples Hospital
Organization:
Peking University Peoples Hospital
Study Overview
Official Title:
A Retrospective Study Investigating the Combination of Irinotecan Vincristine and Anlotinib for Epithelioid Sarcoma
Status:
WITHDRAWN
Status Verified Date:
2023-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Check the IRB again
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Epithelioid sarcoma is a rare soft tissue sarcoma characterized by SMARCB1INI1 deficiency Much attention has been paid to the selective EZH2 inhibitor tazemetostat where other systemic treatments are generally ignored To explore alternative treatment options we studied the effects of irinotecan-based chemotherapy in a series of epithelioid sarcoma patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None